Literature DB >> 16341531

The in vitro antitumor effect and in vivo tumor-specificity distribution of human-mouse chimeric antibody against transferrin receptor.

Ye Qing1, Wang Shuo, Wang Zhihua, Zhu Huifen, Lei Ping, Liu Lijiang, Zhao Xiaorong, Chao Liming, Xiao Daiwen, Huang Yu, Xing Wei, Fang Min, Feng Zuohua, Shen Guanxin.   

Abstract

Transferrin receptor (TfR/CD71) deserves attention as a selective target for cancer therapy due to its higher expression in tumors versus normal tissues. Also, it has been shown the mouse-derived monoclonal antibody against TfR can significantly inhibit the proliferation of tumor cells. Through constructing the chimeric antibody against TfR, the antigenicity of antibody can be weakened, and most importantly, the antitumor effect of antibody can be strengthened by the introduction of the human Fc fragment. In previous studies, we successfully constructed the human-mouse chimeric antibody against TfR (D2C) and demonstrated that its Fab fragment could specially recognize the TfR on the surface of target cells. In this study, through labeling the chimeric antibody D2C with 125I, we calculated the affinity constant (Ka) of 9.34-9.62x10(9) l/mol for this antibody according to the Scatchard drawing method. Moreover, in vivo studies in nude mice-bearing human liver cancer (SMMC-7721) xenografts have shown that the radioactivity distribution ratio of 131I-D2C on T/NT was 2-14:1 or 3-21:1 on the seventh day after intraperitoneal or intratumoral injection of 131I-labeled D2C (131I-D2C). These evidences indicated that the in vivo distribution of D2C display the characteristics of certain tumor-specificity localization. In vitro studies, D2C can induce the apoptosis of K562 through the mitochondria death pathway and arrest the cell at G1 phase, as determined by cell cycle analysis. Using the human tumor cells (K562, CEM, and SMMC-7721) expressing TfR as target cells, and normal human PBMC as effector cells, Fc fragment of D2C can perform both the antibody-dependent cell-mediated cytotoxicity and the complement-dependent cytotoxicity. Together, it was demonstrated that the D2C display a tumor-specificity distribution, and has a strong antitumor effect. Thus, it has the potential therapeutic significance.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16341531     DOI: 10.1007/s00262-005-0105-7

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  17 in total

1.  Targeted delivery of siRNA using transferrin-coupled lipoplexes specifically sensitizes CD71 high expressing malignant cells to antibody-mediated complement attack.

Authors:  Marc Cinci; Srinivas Mamidi; Wenhan Li; Volker Fehring; Michael Kirschfink
Journal:  Target Oncol       Date:  2014-11-15       Impact factor: 4.493

2.  Transferrin-mediated targeting of bacteriophage HK97 nanoparticles into tumor cells.

Authors:  Rick K Huang; Nicole F Steinmetz; Chi-Yu Fu; Marianne Manchester; John E Johnson
Journal:  Nanomedicine (Lond)       Date:  2011-01       Impact factor: 5.307

3.  Preparation and identification of scFv and bsFv against transferrin receptor.

Authors:  Jing Liu; Daiwen Xiao; Xiaoou Zhou; Xue Wen; Hong Dai; Zhihua Wang; Xin Shen; Wei Dai; Daofeng Yang; Guanxin Shen
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2008-12-24

4.  An antibody-based multifaceted approach targeting the human transferrin receptor for the treatment of B-cell malignancies.

Authors:  Tracy R Daniels; Elizabeth Ortiz-Sánchez; Rosendo Luria-Pérez; Rafaela Quintero; Gustavo Helguera; Benjamin Bonavida; Otoniel Martínez-Maza; Manuel L Penichet
Journal:  J Immunother       Date:  2011 Jul-Aug       Impact factor: 4.456

Review 5.  Iron in multiple myeloma.

Authors:  Kristina VanderWall; Tracy R Daniels-Wells; Manuel Penichet; Alan Lichtenstein
Journal:  Crit Rev Oncog       Date:  2013

6.  Insights into the effector functions of human IgG3 in the context of an antibody targeting transferrin receptor 1.

Authors:  Lai Sum Leoh; Tracy R Daniels-Wells; Otoniel Martínez-Maza; Manuel L Penichet
Journal:  Mol Immunol       Date:  2015-07-29       Impact factor: 4.407

7.  Targeting hypoxia-inducible factor-1alpha with Tf-PEI-shRNA complex via transferrin receptor-mediated endocytosis inhibits melanoma growth.

Authors:  Yeqiang Liu; Juan Tao; Yan Li; Jing Yang; Yan Yu; Min Wang; Xiaoyuan Xu; Changzheng Huang; Wei Huang; Jing Dong; Li Li; Jing Liu; Guanxin Shen; Yating Tu
Journal:  Mol Ther       Date:  2008-12-09       Impact factor: 11.454

8.  Antitumour effects of single or combined monoclonal antibodies directed against membrane antigens expressed by human B cells leukaemia.

Authors:  Séverine Loisel; Pierre-Alain André; Josee Golay; Franz Buchegger; Jean Kadouche; Martine Cérutti; Luca Bologna; Marek Kosinski; David Viertl; Angelika Bischof Delaloye; Christian Berthou; Jean-Pierre Mach; Laurence Boumsell
Journal:  Mol Cancer       Date:  2011-04-19       Impact factor: 27.401

9.  Generation and functional characterization of the anti-transferrin receptor single-chain antibody-GAL4 (TfRscFv-GAL4) fusion protein.

Authors:  Qing Ye; Heyu Hu; Zhihua Wang; Tong Lu; Zhiquan Hu; Xing Zeng; Shu Zhang; Jing Liu; Ping Lei; Cong-Yi Wang; Zhangqun Ye; Guanxin Shen
Journal:  BMC Biotechnol       Date:  2012-11-28       Impact factor: 2.563

Review 10.  Anaplastic Thyroid Carcinoma: Current Treatments and Potential New Therapeutic Options with Emphasis on TfR1/CD71.

Authors:  Rosalba Parenti; Lucia Salvatorelli; Gaetano Magro
Journal:  Int J Endocrinol       Date:  2014-07-01       Impact factor: 3.257

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.